An anonymous reader quotes a report from CBC News: Inside a bustling unit at St. Michael's Hospital in downtown Toronto, one of Shirley Bell's patients was suffering from a cat bite and a fever, but otherwise appeared fine -- until an alert from an AI-based early warning system showed he was sicker than he seemed. While the nursing team usually checked blood work around noon, the technology flagged incoming results several hours beforehand. That warning showed the patient's white blood cell count was "really, really high," recalled Bell, the clinical nurse educator for the hospital's general medicine program. The cause turned out to be cellulitis, a bacterial skin infection. Without prompt treatment, it can lead to extensive tissue damage, amputations and even death. Bell said the patient was given antibiotics quickly to avoid those worst-case scenarios, in large part thanks to the team's in-house AI technology, dubbed Chartwatch. "There's lots and lots of other scenarios where patients' conditions are flagged earlier, and the nurse is alerted earlier, and interventions are put in earlier," she said. "It's not replacing the nurse at the bedside; it's actually enhancing your nursing care."

A year-and-a-half-long study on Chartwatch, published Monday in the Canadian Medical Association Journal, found that use of the AI system led to a striking 26 percent drop in the number of unexpected deaths among hospitalized patients. The research team looked at more than 13,000 admissions to St. Michael's general internal medicine ward -- an 84-bed unit caring for some of the hospital's most complex patients -- to compare the impact of the tool among that patient population to thousands of admissions into other subspecialty units. "At the same time period in the other units in our hospital that were not using Chartwatch, we did not see a change in these unexpected deaths," said lead author Dr. Amol Verma, a clinician-scientist at St. Michael's, one of three Unity Health Toronto hospital network sites, and Temerty professor of AI research and education in medicine at University of Toronto. "That was a promising sign."

The Unity Health AI team started developing Chartwatch back in 2017, based on suggestions from staff that predicting deaths or serious illness could be key areas where machine learning could make a positive difference. The technology underwent several years of rigorous development and testing before it was deployed in October 2020, Verma said. Dr. Amol Verma, a clinician-scientist at St. Michael's Hospital who helped lead the creation and testing of CHARTwatch, stands at a computer. "Chartwatch measures about 100 inputs from [a patient's] medical record that are currently routinely gathered in the process of delivering care," he explained. "So a patient's vital signs, their heart rate, their blood pressure ... all of the lab test results that are done every day." Working in the background alongside clinical teams, the tool monitors any changes in someone's medical record "and makes a dynamic prediction every hour about whether that patient is likely to deteriorate in the future," Verma told CBC News.

Neuralink said on Tuesday it has received the FDA's "breakthrough device" designation for its experimental implant aimed at restoring vision. Called Blindsight, the device "will enable even those who have lost both eyes and their optic nerve to see," said Neuralink founder Elon Musk. Reuters reports: The FDA's breakthrough tag is given to certain medical devices that provide treatment or diagnosis of life-threatening conditions. It is aimed at speeding up development and review of devices currently under development. Neuralink did not immediately respond to a request seeking details about when it expects the Blindsight device to move into human trials.

An anonymous reader quotes a report from NBC News: Scientists in Brazil found microplastics in the brain tissue of cadavers, according to a new study published Monday in the journal JAMA Network Open. Mounting research over the last few years has found microplastics in nearly every organ in the body, as well as in the bloodstream and in plaque that clogs arteries. Whether these ubiquitous pollutants can reach the human brain has been a primary concern for scientists. The latest research looked at a part of the brain called the olfactory bulb, which processes information about smell. Humans have two olfactory bulbs, one above each nasal cavity. Connecting the olfactory bulb and the nasal cavity is the olfactory nerve.

Some researchers worry the olfactory pathway may also be an entry point for microplastics getting into the brain, beyond the olfactory bulb. "Previous studies in humans and animals have shown that air pollution reaches the brain, and that particles have been found in the olfactory bulb, which is why we think the olfactory bulb is probably one of the first points for microplastics to reach the brain," said lead study author Dr. Thais Mauad, an associate professor of pathology at the University of Sao Paulo Medical School in Brazil.

Mauad and her team took samples of olfactory bulb tissue from 15 cadavers of people who died between the ages of 33 and 100. Samples from eight of the cadavers contained microplastics -- tiny bits of plastic that ranged from 5.5 micrometers to 26.4 micrometers in size. In total, the researchers found 16 plastic fibers and particles in the tissues. The smallest were slimmer than the diameter of a human red blood cell, which measures about 8 micrometers. The most common type of plastic they found was polypropylene, followed by polyamide, nylon and polyethylene vinyl acetate. "The nose is a major point of defense to keep particles and dust out of the lungs," Campen wrote in an email. "So seeing some plastics in the olfactory system, especially given how they are being found everywhere else in the body, is completely expected." [...] "There is evidence that very small airborne particles can move to the brain via the olfactory bulb, but this is not known to be a major route of trafficking material to the brain," Campen said. Campen notes it's more likely that nanoplastics enter the brain through the bloodstream, which picks up plastic bits from the lungs or digestive tract, rather than the olfactory bulb. "However, it's extremely difficult for particles, even those in pharmaceuticals, to enter the brain through the blood," notes NBC News. "That's because the brain is surrounded by a semipermeable membrane called the blood-brain barrier."

Retraction Watch: A Nobel prize-winning genetics researcher has retracted two more papers, bringing his total to 13. Gregg Semenza, a professor of genetic medicine and director of the vascular program at Johns Hopkins' Institute for Cell Engineering in Baltimore, shared the 2019 Nobel prize in physiology or medicine for "discoveries of how cells sense and adapt to oxygen availability." Since pseudonymous sleuth Claire Francis and others began using PubPeer to point out potential duplicated or manipulated images in Semenza's work in 2019, the researcher has retracted 12 papers. A previous retraction from 2011 for a paper co-authored with Naoki Mori -- who with 31 retractions sits at No. 25 on our leaderboard -- brings the total to 13.

More details on that report about NASA from the Washington Post: NASA is 66 years old and feeling its age. Brilliant engineers are retiring. Others have fled to higher-paying jobs in the private space industry. The buildings are old, their maintenance deferred. The Apollo era, with its huge taxpayer investment, is a distant memory. The agency now pursues complex missions on inadequate budgets. This may be an unsustainable path for NASA, one that imperils long-term success. That is the conclusion of a sweeping report, titled "NASA at a Crossroads," written by a committee of aerospace experts and published Tuesday by the National Academies of Sciences, Engineering and Medicine. The report suggests that NASA prioritizes near-term missions and fails to think strategically. In other words, the space agency isn't sufficiently focused on the future.

NASA's intense focus on current missions is understandable, considering the unforgiving nature of space operations, but "one tends to neglect the probably less glamorous thing that will determine the success in the future," the report's lead author, Norman Augustine, a retired Lockheed Martin chief executive, said Tuesday. He said one solution for NASA's problems is more funding from Congress. But that may be hard to come by, in which case, he said, the agency needs to consider canceling or delaying costly missions to invest in more mundane but strategically important institutional needs, such as technology development and workforce training. Augustine said he is concerned that NASA could lose in-house expertise if it relies too heavily on the private industry for newly emerging technologies. "It will have trouble hiring innovative, creative engineers. Innovative, creative engineers don't want to have a job that consists of overseeing other people's work," he said...

The report is hardly a blistering screed. The tone is parental. It praises the agency — with a budget of about $25 billion — for its triumphs while urging more prudent decision-making and long-term strategizing.

NASA pursues spectacular missions. It has sent swarms of robotic probes across the solar system and even into interstellar space. Astronauts have continuously been in orbit for more than two decades. The most ambitious program, Artemis, aims to put astronauts back on the moon in a few short years. And long-term, NASA hopes to put astronauts on Mars. But a truism in the industry is that space is hard. The new report contends that NASA has a mismatch between its ambitions and its budget, and needs to pay attention to fundamentals such as fixing its aging infrastructure and retaining in-house talent. NASA's overall physical infrastructure is already well beyond its design life, and this fraction continues to grow," the report states.
NASA Administrator Bill Nelson said the report "aligns with our current efforts to ensure we have the infrastructure, workforce, and technology that NASA needs for the decades ahead," according to the article.

Nelson added that the agency "will continue to work diligently to address the committee's recommendations."

An anonymous reader quotes a report from CBC News: Stranded astronauts Butch Wilmore and Suni Williams said Friday it was hard to watch their Boeing capsule return to Earth without them. It was their first public comments since last week's return of the Boeing Starliner capsule that took them to the International Space Station in June. They remained behind after NASA determined the problem-plagued capsule posed too much risk for them to ride back in. "That's how it goes in this business," said Williams, adding that "you have to turn the page and look at the next opportunity."

Wilmore and Williams are now full-fledged station crew members, chipping in on routine maintenance and experiments. They, along with seven others on board, welcomed a Soyuz spacecraft carrying two Russians and an American earlier this week, temporarily raising the station population to 12, a near record. NASA astronauts Butch Wilmore and Suni Williams spoke to the press on Friday for the first time since their Boeing Starliner capsule returned to Earth without them. The two, who have been on the International Space Station since June 6, said they are taking the mission's unexpected extension into 2025 in stride -- even if it means they've had to change their voting plans. The transition to station life was "not that hard" since both had previous stints there, said Williams, who will soon take over as station commander. "This is my happy place. I love being up here in space," she said.

The two Starliner test pilots -- both retired U.S. navy captains and longtime NASA astronauts — will stay at the orbiting laboratory until late February. They have to wait for a SpaceX capsule to bring them back. That spacecraft is due to launch later this month with a reduced crew of two, with two empty seats for Wilmore and Williams for the return leg. The duo said they appreciated all the prayers and well wishes from strangers back home. Wilmore said he will miss out on family milestones such as being around for his youngest daughter's final year of high school. The astronauts, who prepared for eight days in space, will now be up there for eight months, which could have a greater impact on the body. "It is a bit of a change from a sprint to a marathon," said Dr. Adam Sirek of the Canadian Society of Aerospace Medicine.

Researchers have discovered that people with depression have an expanded brain network, specifically the frontostriatal salience network, which is 73% larger compared to healthy individuals. "It's taking up more real estate on the brain surface than we see is typical in healthy controls," said Dr Charles Lynch, a co-author of the research, from Weill Cornell Medicine in New York. He added that expansion meant the size of other -- often neighboring -- brain networks were smaller. The Guardian reports: Writing in the journal Nature, Lynch and colleagues report how they used precision functional mapping, a new approach to brain imaging that analyses a host of fMRI (functional MRI) scans from each individual. The team applied this method to 141 people with depression and 37 people without it, enabling them to measure accurately the size of each participant's brain networks. They then took the average size for each group. They found that a part of the brain called the frontostriatal salience network was expanded by 73% on average in participants with depression compared with healthy controls.

These findings were supported by an analysis of single brain scans previously collected from 932 healthy people and 299 with depression. The team said the size of this brain network in people with depression did not change with time, mood or transcranial magnetic stimulation treatment. However, brain signals between different parts of the network became less synchronised when participants had certain symptoms of depression, with these changes also associated with the severity of future symptoms. The team added that an analysis of brain scans from 57 children who went on to develop depression as adolescents revealed this brain network was expanded years before their symptoms developed, while it was also expanded in adults with late onset depression.

The researchers said this suggested an expanded brain network could be a risk factor for developing depression, rather than a consequence of the condition. However, they said it was unclear to what extent this enlarged network was the result of genetics or experiences, and whether the association with depression arose from this expansion or from other brain networks consequently being smaller. The team added that their results could offer a way to explore whether certain people may be at increased risk of developing depression, and could help develop personalised treatments.

An anonymous reader quotes a report from 404 Media, written by Jason Koebler: I've been videochatting with Mixael Swan Laufer for about 30 minutes about an exciting discovery when he points out that to date, the best way he's been able to bring attention to his organization is "the old school method of me performing a bunch of federal felonies on stage in front of a bunch of people." I stop him and ask: "In this case, what are the felonies?" "Well, the list is pretty long," he said. Laufer is the chief spokesperson of Four Thieves Vinegar Collective, an anarchist collective that has spent the last few years teaching people how to make DIY versions of expensive pharmaceuticals at a tiny fraction of the cost.

Four Thieves Vinegar Collective call what they do "right to repair for your body." Laufer has become well known for handing out DIY pills and medicines at hacking conferences, which include, for example, courses of the abortion drug misoprostol that can be manufactured for 89 cents (normal cost: $160) and which has become increasingly difficult to obtain in some states following the Supreme Court decision in Dobbs. In our call, Laufer had just explained that Four Thieves' had made some miscalculations as part of its latest project, to create instructions for replicating sofosbuvir (Sovaldi), a miracle drug that cures hepatitis C, which he planned to explain and reveal at the DEF CON hacking conference. Unlike many other drugs that treat viruses, Sovaldi does not suppress hepatitis C, a virus that kills roughly 250,000 people around the world each year. It cures it. [...]

Crucially, unlike other medical freedom organizations, Four Thieves isn't suggesting people treat COVID with Ivermectin, isn't shilling random supplements, and doesn't have any sort of commercial arm at all. Instead, they are helping people to make their own, identical pirated versions of proven and tested pharmaceuticals by taking the precursor ingredients and performing the chemical reactions to make the medication themselves. "We don't invent anything, really," Laufer said. "We take things that are on the shelf and hijack them. We like to take something established, and be like 'This works, but you can't get it.' Well, here's a way to get it." A slide at his talk reads "Isn't this illegal? Yeah. Grow up." Four Thieves has developed a suite of open-source tools to help achieve its goal. The core tool, Chemhacktica, is a software platform that uses machine learning to map chemical pathways for synthesizing desired molecules. It suggests potential chemical reactions, identifies precursor materials, and checks their availability for purchase.

The other is Microlab, an open-source controlled lab reactor built from affordable, off-the-shelf components costing between $300 and $500. It uses Chemhacktica's suggested pathways to create medications, and detailed instructions for building and operating the Microlab are provided. Additionally, the company developed a drag-and-drop recipe system called Apothecarium that generates executable files for the Microlab, offering step-by-step guidance on producing specific medications.

Laufer told 404 Media: "I am of the firm belief that we are hitting a watershed where economics and morality are coming to a head, like, 'Look: intellectual property law is based off some ideas that came out of 1400s Venice. They're not applicable and they're being abused and people are dying every day because of it, and it's not OK.'"

Further reading: Meet the Anarchists Making Their Own Medicine (Motherboard; 2018)

An anonymous Slashdot reader shared this report from NBC News: A new approach to a routine blood test could predict a person's 30-year risk of heart disease, research published Saturday in the New England Journal of Medicine found.

Doctors have long assessed their patients' risk for cardiovascular disease by using a blood test to look at cholesterol levels, focusing particularly on LDL or "bad" cholesterol. But limiting blood testing to just cholesterol misses important — and usually silent — risk factors, experts say... Lead study author Dr. Paul Ridker, director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital in Boston and his team found that in addition to LDL cholesterol, two other markers — a type of fat in the blood called lipoprotein (a), or Lp(a), and an indicator of inflammation — are important predictors of a person's risk of heart attack, stroke and coronary heart disease...

In the study, the researchers analyzed data from nearly 30,000 U.S. women who were part of the Women's Health Study. On average, the women were 55 years old when they enrolled in the years 1992 through 1995. About 13% — roughly 3,600 participants — had either a heart attack or stroke, had surgery to fix a narrowed or blocked artery, or died from heart disease over the 30-year follow-up period... All of the women had blood tests done at the beginning of the study to measure their LDL cholesterol, Lp(a) and C-reactive protein levels, a marker of inflammation in the body. These measurements, individually as well as together, appeared to predict a woman's heart health over the next three decades, the study found.

Women with the highest levels of LDL cholesterol had a 36% higher risk for heart disease compared with those with the lowest levels. The highest levels of Lp(a) indicated a 33% elevated risk, and those with the highest levels of CRP were 70% more at risk for heart disease. When the three were looked at together, women who had the highest levels were 1.5 times more likely to have a stroke and over three times more likely to develop coronary heart disease over the next 30 years compared with women with the lowest levels.

All of the markers have been individually linked to higher risk of heart disease, but "all three represent different biological processes. They tell us why someone is actually at risk," Ridker said.

The Wall Street Journal reports that long Covid "has pushed around one million Americans out of the labor force, economists estimate." More than 5% of adults in the U.S. have long Covid, and it is most prevalent among Americans in their prime working years. About 3.6 million people reported significantly modifying their activities because of the illness in a recent survey by the Centers for Disease Control and Prevention.

Long Covid is a chronic condition with symptoms lasting at least three months after a Covid infection, according to the CDC. Symptoms include fatigue, changes in memory, shortness of breath and trouble concentrating. Long Covid can make tasks as simple as responding to an email arduous, people with the condition say. They struggle to summon the right word or manage stress. Among its many symptoms is post-exertional malaise, which can worsen after even minor physical or mental activity. "People can't go back to work or have to significantly cut down on the amount of work that they can handle," said Akiko Iwasaki, an immunobiology professor at Yale School of Medicine.

Researchers don't know how long symptoms can last. Few people with long Covid have fully recovered within two years. Patients say their doctors have tried everything from antihistamines to blood thinners to physical therapy to acupuncture. Some people might live with the condition for the rest of their lives, said Dr. Paul Volberding, a professor emeritus at the University of California, San Francisco...

Some people with long Covid, which the federal government has classified as a disability, have stayed in their jobs. Human-resource managers have made accommodations including remote work, flexible hours or modified responsibilities, said Rue Dooley of the Society for Human Resource Management. "It's not going away," he said. "It's going to be one of another 100 conditions that we have to grapple with."

People were more likely to develop long Covid at the start of the pandemic, according to a study published in July in the New England Journal of Medicine. The proliferation of vaccines and changes to the virus have made people infected with Covid less likely to develop long Covid.

An anonymous reader quotes a report from the New York Times: Melted capsules. Cloudy insulin. Pills that may no longer work. Doctors and pharmacists say the scorching temperatures enveloping the country could be endangering people's health in an unexpected way: by overheating their medications. Millions of Americans now receive their prescription medications through mail-order shipments, either for convenience or because their health plans require it. But the temperatures inside the cargo areas of delivery trucks can reach 150 degrees Fahrenheit in the summer, according to drivers -- far exceeding the range of 68 to 77 degrees recommended by the national organization that sets standards for drug handling.

Mail-order pharmacies say that their packaging is weather resistant and that they take special precautions when medication "requires specific temperature control." But in a study published last year, independent pharmaceutical researchers who embedded data-logging thermometers inside simulated shipments found that the packages had spent more than two-thirds of their transit time outside the appropriate temperature range, "regardless of the shipping method, carrier, or season." Extreme temperatures can alter the components in many medications, from pancreatic enzymes to the thyroid replacement drug levothyroxine to oral contraceptives, medical experts say.

Dr. Mike Ren, a primary care physician and an assistant professor in the department of family and community medicine at the Baylor College of Medicine, said that liquid medications like insulin or AUVI-Q, the epinephrine injection for allergic reactions, are often at heightened risk of degradation because excessive heat exposure can cause the evaporation of liquid components that were compounded at precise ratios. Aerosolized medications, too, are uniquely vulnerable because of the risk of pressure changes in the canister. "Doctors recommend picking up your prescriptions at a local pharmacy whenever possible during hot summer months, particularly if your medication is liquid or aerosolized," notes the report. "If you are enrolled in an insurance program that requires using a mail-order pharmacy, ask for an exception during the summer or, at the very least, contact the on-call pharmacist at the mail-order company to get more information about shipping practices and to ask for temperature-controlled packaging. You should do this even if the drug does not require refrigeration."

Once you do get your medication, you should make sure to preserve it in a cool, dry environment, away from direct sunlight. If you're flying, your prescriptions should be stored in your carry-on bag. They should never be left in a parked car.

"Lenacapavir is not a new drug," reports NPR. "It's been approved by the FDA in the United States for multi-drug resistant HIV treatment since 2022."

But instead of treating HIV, what if it were used for preventing infections? The treatment consists of a twice-yearly injection... Early trial results were released in June and generated great excitement, indicating 100% efficacy. On Wednesday, July 24, the full peer-reviewed results were released at the AIDS 2024 conference, confirming the preliminary data... This treatment offers an alternative to the current standard of core for HIV prevention efforts for over a decade: taking a pill like Truvada every day...

Any eventual approval and widespread use would come with challenges... Lenacapavir's cost as HIV treatment in the United States in 2023 was $42,250 per new patient per year. Oral PrEP options, on the other hand, can cost less than $4 a month. "The biggest gap in prevention isn't medication, it's accessing medications," says Dr. Philip Grant, clinical associate professor and director of the HIV clinic at Stanford University School of Medicine.

Activists across Uganda and South Africa have urged Gilead Sciences to license lenacapavir to the Medicines Patent Pool — a United Nations-backed organization that partners with governments, industry and other organizations to license medications. This would allow for manufacturing of generic versions of the drug at a fraction of the cost... [A] group of Médecins Sans Frontières activists gathered at AIDS 2024 and called for an "immediate global action to break Gilead's monopoly on lenacapavir."
In a statement Gilead said they couldn't set a price because the drug had not yet been approved — but that Gilead "is committed to access pricing for high-incidence, resource-limited countries." Gilead will ensure dedicated supply of lenacapavir for HIV prevention in the countries where the need is greatest until voluntary licensing partners are able to supply high-quality, low-cost versions of lenacapavir.â

Gilead is developing a robust direct voluntary licensing program to expedite access to those versions of lenacapavir in high-incidence, resource-limited countries. We are moving with urgency to negotiate these contracts.

An anonymous reader quotes a report from the New York Times: The image, as it happens, comes from dozens of brain scans produced by researchers at Washington University School of Medicine in St. Louis who gave psilocybin, the compound in "magic mushrooms," to participants in a study before sending them into a functional M.R.I. scanner. The kaleidoscopic whirl of colors they recorded is essentially a heat map of brain changes, with the red, orange and yellow hues reflecting a significant departure from normal activity patterns. The blues and greens reflect normal brain activity that occurs in the so-called functional networks, the neural communication pathways that connect different regions of the brain.

The scans, published Wednesday in the journal Nature, offer a rare glimpse into the wild neural storm associated with mind-altering drugs. Researchers say they could provide a potential road map for understanding how psychedelic compounds like psilocybin, LSD and MDMA can lead to lasting relief from depression, anxiety and other mental health disorders. "Psilocybin, in contrast to any other drug we've tested, has this massive effect on the whole brain that was pretty unexpected," said Dr. Nico Dosenbach, a professor of neurology at Washington University and a senior author of the study. "It was quite shocking when we saw the effect size." Brian Mathur, a systems neuroscientist at the University of Maryland School of Medicine in Baltimore, says these findings cannot show exactly what causes the therapeutic benefit of psilocybin, but "it's possible psilocybin is directly causing" the brain-network changes. That, or it is creating a psychedelic experience that in turn causes parts of the brain to behave differently.

The next step is to determine whether psilocybin's blood-flow changes in the brain or its direct effects on neurons, or both, are responsible for the brain-network disruptions. "The best part of this work is that it's going to provide a means forward for the field to develop further hypotheses that can and should be tested," Mathur says.

An anonymous reader shared this report from the Guardian: A team of researchers from the UK and US have found that pancreatic cancer is able to shut down molecules in one of the body's most important genes, helping the disease to grow and spread rapidly... Dr Maria Hatziapostolou, of Nottingham Trent University's John van Geest Cancer Research Centre, said: "This work, which has provided new understanding and knowledge of how the cancer behaves, will hopefully help pave the way for potential new treatments in the future...."

For the study, published in the journal Gastro Hep Advances, the researchers analysed healthy as well as pancreatic cancer tissue samples. They found pancreatic cancers triggered a process known as DNA methylation, causing molecules in the normally beneficial HNF4A gene to switch off, allowing tumours to grow extremely quickly. The HNF4A gene is crucial to human health because it helps many of the body's organs to function properly. But the researchers discovered pancreatic cancer can covertly disable the gene's benefits. Hatziapostolou said: "Loss of HNF4A drives pancreatic cancer development and aggressiveness and we now know correlates with poor patient survival."

Scientists from the University of Nottingham, Stanford University and the University of California and Cedars-Sinai medical centre, Los Angeles, were also involved in the project.
The published study calls the targeted HNF4A gene is "a novel tumor suppressor in pancreatic cancer, regulating cancer growth and aggressiveness."

And ultimately, according to the Guardian, pancreatic cancer "is the 12th most common cancer worldwide," according to the Guardian, "with more than half a million people diagnosed every year. It has the worst survival rates of all the most common forms of the disease."

The researchers paper ends with this conclusion. "HNF4A silencing... drives pancreatic cancer development and aggressiveness leading to poor patient survival."

"In a significant advancement for space technology, a team of UC Berkeley researchers, led by doctoral student Taylor Waddell, successfully launched a 3D printer into space," reports the university's student newspaper: As part of the Virgin Galactic 07 mission, the team sent a 3D printer named SpaceCAL to space to explore the potential of Computed Axial Lithography, or CAL, and additive manufacturing in space... During its 140-second flight in suborbital space, the SpaceCAL printer autonomously detected microgravity and printed four test parts: two space shuttles and two Benchies, or 3D-printed boats created to check the printer's accuracy, according to Sean Chu, a member of the team who worked on designing structures and mechanisms. Within the 140 seconds, the process involved multiple steps such as printing, post-washing, flushing with water and post-curing with light to fully solidify the parts.
But that's just the beginning, says the university's engineering department: To date, CAL has shown that it can successfully print with more than 60 different materials on Earth, such as silicones, glass composites and biomaterials. According to Waddell, this versatility could come in handy for both the cabin and the crew... "CAL is also capable of repairing the crew. We can print dental replacements, skin grafts or lenses, or things personalized in emergency medicine for astronauts, which is very important in these missions, too."

Someday, CAL may be used to print even more sophisticated parts, such as human organs. Lawrence Livermore National Lab has received a grant from NASA to test this technology on the International Space Station. "They're going to basically do bioprinting on the Space Station," said Waddell. "And the long, long-term goal is to print organs up in space with CAL, then bring them back down to Earth." Next, Waddell and his colleagues hope to begin work with NASA on developing and validating a single object that could support crew health and wellness, like a dental crown for an astronaut or a surgical wound closure tool...

This project was made possible through a $1.4 million grant and engineering support provided by NASA. In addition, Virgin Galactic played a pivotal role in taking this project to the next level.

Longtime Slashdot reader ArchieBunker shares a report from TIME Magazine: On an evening in December 2023, 43-year-old small business owner Sarah Rosenkranz collapsed in her home in Granbury, Texas and was rushed to the emergency room. Her heart pounded 200 beats per minute; her blood pressure spiked into hypertensive crisis; her skull throbbed. "It felt like my head was in a pressure vise being crushed," she says. "That pain was worse than childbirth." Rosenkranz's migraine lasted for five days. Doctors gave her several rounds of IV medication and painkiller shots, but nothing seemed to knock down the pain, she says. This was odd, especially because local doctors were similarly vexed when Indigo, Rosenkranz's 5-year-old daughter, was taken to urgent care earlier that year, screaming that she felt a "red beam behind her eardrums." It didn't occur to Sarah that these symptoms could be linked. But in January 2024, she walked into a town hall in Granbury and found a room full of people worn thin from strange, debilitating illnesses. A mother said her 8-year-old daughter was losing her hearing and fluids were leaking from her ears. Several women said they experienced fainting spells, including while driving on the highway. Others said they were wracked by debilitating vertigo and nausea, waking up in the middle of the night mid-vomit. None of them knew what, exactly, was causing these symptoms. But they all shared a singular grievance: a dull aural hum had crept into their lives, which growled or roared depending on the time of day, rattling their windows and rendering them unable to sleep. The hum, local law enforcement had learned, was emanating from a Bitcoin mining facility that had recently moved into the area -- and was exceeding legal noise ordinances on a daily basis.

Over the course of several months in 2024, TIME spoke to more than 40 people in the Granbury area who reported a medical ailment that they believe is connected to the arrival of the Bitcoin mine: hypertension, heart palpitations, chest pain, vertigo, tinnitus, migraines, panic attacks. At least 10 people went to urgent care or the emergency room with these symptoms. The development of large-scale Bitcoin mines and data centers is quite new, and most of them are housed in extremely remote places. There have been no major medical studies on the impacts of living near one. But there is an increasing body of scientific studies linking prolonged exposure to noise pollution with cardiovascular damage. And one local doctor -- ears, nose, and throat specialist Salim Bhaloo -- says he sees patients with symptoms potentially stemming from the Bitcoin mine's noise on an almost weekly basis. "I'm sure it increases their cortisol and sugar levels, so you're getting headaches, vertigo, and it snowballs from there," Bhaloo says. "This thing is definitely causing a tremendous amount of stress. Everyone is just miserable about it." "By the end of 2024, we intend to have replaced the majority of air-cooled containers with immersion cooling, with no expansion required," said a representative for Marathon Digital Holdings, the company that owns the mine. "Initial sound readings on immersion containers indicate favorable results in sound reduction and compliance with all relevant state noise ordinances." They did not answer questions about the health impacts their mining site was causing.

"We're living in a nightmare," said Rosenkranz. She clocked the hum at 72 decibels in Indigo's bedroom in the dead of night. "Indigo's room directly faces the mine, which sits about a mile and a half away," notes TIME. She had to be pulled from her school after she developed so many ear infections from the sound.

The report also said a resident's dog "started going bald and developed debilitating anxiety shortly after the Bitcoin mine began operating four blocks away." TIME added: "Directly next door, Tom Weeks' dog Jack Rabbit Slim started shaking and hyperventilating uncontrollably for hours on end; a vet placed him on the seizure medication Gabapentin. Rosenkranz's chickens stopped laying eggs for months. And Jerry and Patricia Campbell's centuries-old oak tree, which had served as the family's hub and protector for generations of backyard family reunions and even a wedding, died suddenly three months ago."

OpenAI CEO Sam Altman and businesswoman Arianna Huffington have announced they're working on an "AI health coach" via Thrive AI Health. According to a Time magazine op-ed, the two executives said that the bot will be trained on "the best peer-reviewed science" alongside "the personal biometric, lab, and other medical data you've chosen to share with it." The Verge reports: The company tapped DeCarlos Love, a former Google executive who previously worked on Fitbit and other wearables, to be CEO. Thrive AI Health also established research partnerships with several academic institutions and medical centers like Stanford Medicine, the Rockefeller Neuroscience Institute at West Virginia University, and the Alice L. Walton School of Medicine. (The Alice L. Walton Foundation is also a strategic investor in Thrive AI Health.) Thrive AI Health's goal is to provide powerful insights to those who otherwise wouldn't have access -- like a single mother looking for quick meal ideas for her gluten-free child or an immunocompromised person in need of instant advice in between doctor's appointments. [...]

The bot is still in its early stages, adopting an Atomic Habits approach. Its goal is to gently encourage small changes in five key areas of your life: sleep, nutrition, fitness, stress management, and social connection. By making minor adjustments, such as suggesting a 10-minute walk after picking up your child from school, Thrive AI Health aims to positively impact people with chronic conditions like heart disease. It doesn't claim to be ready to provide real diagnosis like a doctor would but instead aims to guide users into a healthier lifestyle. "AI is already greatly accelerating the rate of scientific progress in medicine -- offering breakthroughs in drug development, diagnoses, and increasing the rate of scientific progress around diseases like cancer," the op-ed read.

Starting this fall, most students at Johns Hopkins' medical school will attend tuition-free thanks to a $1 billion donation from billionaire Mike Bloomberg. From a report: The generous gift is intended to address "twin challenges of declining levels of health and education," Bloomberg said in a letter Monday. The donation will cover the full cost of tuition for medical students from families earning less than $300,000, Bloomberg Industries announced Monday. It will also cover living expenses and other fees for students from families earning up to $175,000.

Currently, nearly two-thirds of medical students at the school qualify for financial aid. Johns Hopkins' medical students graduate with an average student loan debt of about $104,000. The donation will also increase financial aid at some of the university's other graduate schools, including the schools of nursing and public health.

A controversial organ retrieval technique is gaining traction across the U.S., promising to alleviate chronic organ shortages but also sparking intense ethical debates, NPR reports. Normothermic regional perfusion, now used by half of the nation's organ procurement organizations, restores blood flow to organs after cardiac death. Proponents argue it increases viable organ supply and improves transplant outcomes. Critics, however, question whether the procedure blurs the definition of death.

A Wall Street Journal analysis has revealed that private insurers in the government's Medicare Advantage program, including UnitedHealth Group, have made numerous questionable diagnoses leading to increased taxpayer-funded payments between 2018 and 2021.

The investigation found instances where patients were diagnosed with conditions they did not have, such as diabetic cataracts and HIV, often without their knowledge. These diagnoses resulted in higher payments from Medicare to the insurers. The Centers for Medicare and Medicaid Services said they are implementing changes to ensure "taxpayer dollars are appropriately spent." The story adds: In all, Medicare paid insurers about $50 billion for diagnoses added just by insurers in the three years ending in 2021, the Journal's analysis showed.